Jee Bang1, Iryna V Lobach2, Anthony E Lang3, Murray Grossman4, David S Knopman5, Bruce L Miller1, Lon S Schneider6, Rachelle S Doody7, Andrew Lees8, Michael Gold9, Bruce H Morimoto10, Adam L Boxer1. 1. Memory and Aging Center, Department of Neurology, University of California San Francisco, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, USA 94158. 2. Department of Epidemiology and Biostatistics, Division of Biostatistics, University of California San Francisco, 550 16th Street, San Francisco, CA, USA 94158. iryna.lobach@ucsf.edu. 3. Department of Neurology, University of Toronto, 399 Bathurst St, McLaughlin 7-418, Toronto, ON, M5T 2S8, Canada. lang@uhnresearch.ca. 4. Department of Neurology, University of Pennsylvania, 3400 Spruce St, Philadelphia, PA, USA 19104. mgrossma@mail.med.upenn.edu. 5. Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA 55905. knopman@mayo.edu. 6. Department of Psychiatry and the Behavioral Sciences and Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. lschneid@usc.edu. 7. Department of Neurology, Baylor College of Medicine, 6550 Fannin St # 1801, Houston, TX, USA 77030. rdoody@bcm.edu. 8. Institute of Neurology, University College of London, 1 Wakefield Street - London - WC1N 1PJ, UK. alees@ion.ucl.ac.uk. 9. UCB BioSciences, Research Triangle, NC, USA. michael.gold.md@gmail.com. 10. Celerion, 621 Rose St, Lincoln, NE 68502, USA. bhmorimoto@gmail.com.
Abstract
INTRODUCTION: Clinical and MRI measurements can track disease progression in PSP, but many have not been extensively evaluated in multicenter clinical trials. We identified optimal measures to capture clinical decline and predict disease progression in multicenter PSP trials. METHODS: Longitudinal clinical rating scales, neuropsychological test scores, and volumetric MRI data from an international, phase 2/3 clinical trial of davunetide for PSP (intent to treat population, n = 303) were used to identify measurements with largest effect size, strongest correlation with clinical change, and best ability to predict dropout or clinical decline over one year as measured by PSP Rating Scale (PSPRS). RESULTS: Baseline cognition as measured by Repeatable Battery for Assessing Neuropsychological Status (RBANS) was associated with attrition, but had only a small effect. PSPRS and Clinical Global Impression (CGI) had the largest effect size for measuring change. Annual change in CGI, RBANS, color trails, and MRI midbrain and ventricular volumes were most strongly correlated with annual PSPRS and had the largest effect sizes for detecting annual change. At baseline, shorter disease duration, more severe depression, and lower performance on RBANS and executive function tests were associated with faster worsening of the PSPRS in completers. With dropouts included, SEADL, RBANS, and executive function tests had significant effect on PSPRS trajectory of change. CONCLUSION: Baseline cognitive status and mood influence the rate of disease progression in PSP. Multiple clinical, neuropsychological, and volumetric MRI measurements are sensitive to change over one year in PSP and appropriate for use in multicenter clinical trials.
INTRODUCTION: Clinical and MRI measurements can track disease progression in PSP, but many have not been extensively evaluated in multicenter clinical trials. We identified optimal measures to capture clinical decline and predict disease progression in multicenter PSP trials. METHODS: Longitudinal clinical rating scales, neuropsychological test scores, and volumetric MRI data from an international, phase 2/3 clinical trial of davunetide for PSP (intent to treat population, n = 303) were used to identify measurements with largest effect size, strongest correlation with clinical change, and best ability to predict dropout or clinical decline over one year as measured by PSP Rating Scale (PSPRS). RESULTS: Baseline cognition as measured by Repeatable Battery for Assessing Neuropsychological Status (RBANS) was associated with attrition, but had only a small effect. PSPRS and Clinical Global Impression (CGI) had the largest effect size for measuring change. Annual change in CGI, RBANS, color trails, and MRI midbrain and ventricular volumes were most strongly correlated with annual PSPRS and had the largest effect sizes for detecting annual change. At baseline, shorter disease duration, more severe depression, and lower performance on RBANS and executive function tests were associated with faster worsening of the PSPRS in completers. With dropouts included, SEADL, RBANS, and executive function tests had significant effect on PSPRS trajectory of change. CONCLUSION: Baseline cognitive status and mood influence the rate of disease progression in PSP. Multiple clinical, neuropsychological, and volumetric MRI measurements are sensitive to change over one year in PSP and appropriate for use in multicenter clinical trials.
Authors: Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs Journal: Parkinsonism Relat Disord Date: 2011-11-13 Impact factor: 4.891
Authors: I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee Journal: Neurology Date: 1996-07 Impact factor: 9.910
Authors: Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto Journal: Lancet Neurol Date: 2014-05-27 Impact factor: 44.182
Authors: Eduardo Tolosa; Irene Litvan; Günter U Höglinger; David Burn; Andrew Lees; María V Andrés; Belén Gómez-Carrillo; Teresa León; Teodoro Del Ser Journal: Mov Disord Date: 2014-02-14 Impact factor: 10.338
Authors: Kevin Duff; Dana McDermott; Dan Luong; Christopher Randolph; Adam L Boxer Journal: J Clin Exp Neuropsychol Date: 2019-02-04 Impact factor: 2.475
Authors: Sandy J Lwi; Brett Q Ford; James J Casey; Bruce L Miller; Robert W Levenson Journal: Proc Natl Acad Sci U S A Date: 2017-06-27 Impact factor: 11.205
Authors: Maura Malpetti; Luca Passamonti; Peter Simon Jones; Duncan Street; Timothy Rittman; Timothy D Fryer; Young T Hong; Patricia Vàsquez Rodriguez; William Richard Bevan-Jones; Franklin I Aigbirhio; John Tiernan O'Brien; James Benedict Rowe Journal: J Neurol Neurosurg Psychiatry Date: 2021-03-17 Impact factor: 13.654
Authors: Marta F Pereira; Tim Buchanan; Günter U Höglinger; Marko Bogdanovic; George Tofaris; Simon Prangnell; Nagaraja Sarangmat; James J FitzGerald; Chrystalina A Antoniades Journal: BMJ Neurol Open Date: 2022-01-21
Authors: David J Whiteside; P Simon Jones; Boyd C P Ghosh; Ian Coyle-Gilchrist; Alexander Gerhard; Michele T Hu; Johannes C Klein; P Nigel Leigh; Alistair Church; David J Burn; Huw R Morris; James B Rowe; Timothy Rittman Journal: Neurobiol Aging Date: 2021-07-16 Impact factor: 4.673
Authors: Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer Journal: Neurotherapeutics Date: 2020-10 Impact factor: 7.620
Authors: Lawren VandeVrede; Marian L Dale; Scott Fields; Megan Frank; Emma Hare; Hilary W Heuer; Kellie Keith; Mary Koestler; Peter A Ljubenkov; Dana McDermott; Noelle Ohanesian; Jennifer Richards; Julio C Rojas; Elisabeth H Thijssen; Christine Walsh; Ping Wang; Amy Wolf; Joseph F Quinn; Richard Tsai; Adam L Boxer Journal: Mov Disord Clin Pract Date: 2020-04-10